Previous studies have shown that chronic GCG receptor agonism increased circulating FGF21 in mice and acute glucagon administration transiently increased FGF21 levels in humans 25
But medical literature evidence suggests these same pathways may interfere with key skin functions by: Slowing fibroblast activity, reducing the production of structural proteins like collagen and elastin Decreasing cell turnover, leading to dullness and slower skin renewal Compromising the skin barrier, increasing water loss and sensitivity to environmental damage The result
In this study, we did not compare to a population who was not receiving GLP-1 RA prescriptions
They can be effectively managed through patient education, dietary changes, gradual dose titration, and short-term pharmacological support when necessary
These follow-on patents form a systematic attempt to add barriers of entry for generic competitors, with the intention of extending Novo Nordisks market monopoly for as long as possible when the main compound patent on the underlying active ingredient, semaglutide, expires
